• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
RGNX

RGNX

REGENXBIO Inc.

NASDAQHealthcareBiotechnologyUS

USD6.69

+0.17 (+2.61%)

Rating:D+

Company Profile

CEO

Curran Simpson

IPO Date

2015-09-17

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$6.73

Prev. Close

$6.52

Day Low

$6.53

Day High

$6.77

52W Low

$5.46

52W High

$16.19

Market Cap

$0.35B

Volume

1.28M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

22.1%

Avg Negative

3.0%

Avg Neutral

75.0%

News Feed

Regenxbio: Suprachoroidal Data May Impress

Seeking Alpha·7/6/2021·↑ positive

REGENXBIO to Participate in Upcoming Investor Conferences

PRNewsWire·6/9/2021·↑ positive

Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years

Benzinga·5/14/2021·↑ positive

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting

PRNewsWire·5/14/2021·↑ positive

Regenxbio: An Overlooked Gene Therapy Innovator

Seeking Alpha·5/14/2021·↑ positive

Regenxbio: Better Investment Case Than Adverum

Seeking Alpha·5/12/2021·↑ positive

Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/5/2021·↓ negative

REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights

PRNewsWire·4/28/2021·↑ positive

REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting

PRNewsWire·4/27/2021·↑ positive